PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.30%
Cash & equivalents declining -15.30% while AVXL's grows 10.68%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-15.30%
Below half of AVXL's 10.68%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
Below half of AVXL's 11.80%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-12.74%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-1.64%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Below half of AVXL's 11.77%. Michael Burry sees a potential red flag for stagnation or capital shortage.
72.22%
Less than half of AVXL's 157.07%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.94%
Similar yoy changes to AVXL's -100.00%. Walter Schloss finds parallel near-term liability trends.
32.21%
Less than half of AVXL's 146.42%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
Less than half of AVXL's 146.42%. David Dodd sees far fewer liability expansions relative to competitor.
0.06%
Less than half of AVXL's 2.75%. David Dodd sees fewer share issuances vs. competitor.
-3.27%
0.5-0.75x AVXL's -5.97%. Martin Whitman is wary of weaker retention or lower profitability.
0.51%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-24.85%
Below half AVXL's 3.42%. Michael Burry sees potential underperformance in building shareholder capital.
-15.58%
Below half AVXL's 11.77%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.30%
Less than half of AVXL's -10.68%. David Dodd sees better deleveraging or stronger cash buildup than competitor.